Table 3.

Propensity score analysis on the effect of immunosuppressive therapy

Control GroupTreatment GroupP
n3939
Patients per era (era 1, 2, 3, respectively)11, 20, 85, 25, 9>0.1
At presentation
    female gender (%)1826>0.1
    age50 ± 1549 ± 13>0.1
    CrCl (ml/min per 1.73 m2)76 ± 2677 ± 23>0.1
    MAP (mmHg)100 ± 12101 ± 12>0.1
    proteinuria (g/d)
        initial9.5 (6.4 to 11.7)6.9 (5.1 to 10.5)>0.1
        peak12.2 (9.1 to 16.8)11.5 (10.0 to 15.6)>0.1
    number of antihypertensive drugs0 (0 to 1)0 (0 to 1)>0.1
Therapy during follow-up
    number of antihypertensive drugs0.7 (0.3 to 1.2)0.7 (0.1 to 1.3)>0.1
    RAS blockade (%)4139>0.1
        duration (% of patient follow-up)43 (7 to 74)45 (28 to 85)>0.1
    immunosuppression
        cyclophosphamide/chlorambucil (n)32/1aBy design
        cyclosporine (n)12a
        corticosteroids (n)25
Clinical follow-up
    MAP (mmHg)102 ± 9101 ± 9>0.1
    proteinuria
        change from peak to last (g/d)−4.7 (−9.8 to −1.6)−9.1 (−14.4 to −5.2)0.01
        absence of remission (%)56210.01
    slope (ml/min per 1.73 m2 per year)−6.1 ± 11.0−3.6 ± 6. 8>0.1
    renal survivalSee Figure 3
  • Values are expressed as mean ± SD or median (interquartile range). CrCl, Creatinine clearance; MAP, mean arterial pressure.

  • a All patients received either cytotoxic or cyclosporine treatment (six patients received both during follow-up).